Rajan MB, Bhardwaj A, Singh S, et al. - In the present study, the researchers sought to compare hair regrowth and local side effects of various concentrations of intralesional triamcinolone acetonide (TA) in scalp alopecia areata (AA) utilizing clinical and dermoscopic parameters. A double‐blind randomized control trial with four treatment groups (10, 5, 2.5 mg/ml TA and normal saline [NS]) was performed between March 2018 and August 2019. It may be better to start with 2.5 mg/mL intralesional TA in limited scalp AA patients based on the clinical benefit and adverse risk assessment from the study. Based on the serial clinical and dermoscopic response, it can be inferred that TA concentration can be increased as a step-up regimen.